Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 73

1.

Molecular treatments in Duchenne muscular dystrophy.

Guglieri M, Bushby K.

Curr Opin Pharmacol. 2010 Jun;10(3):331-7. doi: 10.1016/j.coph.2010.03.005. Epub 2010 Apr 29. Review.

PMID:
20434401
2.

Genetic therapeutic approaches for Duchenne muscular dystrophy.

Foster H, Popplewell L, Dickson G.

Hum Gene Ther. 2012 Jul;23(7):676-87. doi: 10.1089/hum.2012.099. Review.

PMID:
22647146
3.

[Mutation-specific treatments for Duchenne muscular dystrophy].

Matsuo M, Takeshima Y.

Brain Nerve. 2009 Aug;61(8):915-22. Review. Japanese.

PMID:
19697880
4.

[Nonsense readthrough therapy for Duchenne muscular dystrophy].

Takeshima Y.

Rinsho Shinkeigaku. 2014;54(12):1074-6. doi: 10.5692/clinicalneurol.54.1074. Review. Japanese.

PMID:
25672712
5.

New developments in the use of gene therapy to treat Duchenne muscular dystrophy.

Jarmin S, Kymalainen H, Popplewell L, Dickson G.

Expert Opin Biol Ther. 2014 Feb;14(2):209-30. doi: 10.1517/14712598.2014.866087. Epub 2013 Dec 6. Review.

PMID:
24308293
6.

Therapy for Duchenne muscular dystrophy: renewed optimism from genetic approaches.

Fairclough RJ, Wood MJ, Davies KE.

Nat Rev Genet. 2013 Jun;14(6):373-8. doi: 10.1038/nrg3460. Epub 2013 Apr 23. Review.

PMID:
23609411
7.

Exon skipping for nonsense mutations in Duchenne muscular dystrophy: too many mutations, too few patients?

Yokota T, Duddy W, Echigoya Y, Kolski H.

Expert Opin Biol Ther. 2012 Sep;12(9):1141-52. doi: 10.1517/14712598.2012.693469. Epub 2012 Jun 1. Review.

PMID:
22650324
8.

Adeno-Associated Virus (AAV) Mediated Dystrophin Gene Transfer Studies and Exon Skipping Strategies for Duchenne Muscular Dystrophy (DMD).

Kawecka K, Theodoulides M, Hasoglu Y, Jarmin S, Kymalainen H, Le-Heron A, Popplewell L, Malerba A, Dickson G, Athanasopoulos T.

Curr Gene Ther. 2015;15(4):395-415. Review.

PMID:
26159373
9.

Exon-skipping therapy for Duchenne muscular dystrophy.

Nakamura A, Takeda S.

Neuropathology. 2009 Aug;29(4):494-501. doi: 10.1111/j.1440-1789.2009.01028.x. Epub 2009 May 22. Review.

PMID:
19486303
10.

Splice modification to restore functional dystrophin synthesis in Duchenne muscular dystrophy.

Wilton SD, Fletcher S.

Curr Pharm Des. 2010;16(8):988-1001. Review.

PMID:
20041827
11.

Advances in genetic therapeutic strategies for Duchenne muscular dystrophy.

Guiraud S, Chen H, Burns DT, Davies KE.

Exp Physiol. 2015 Dec;100(12):1458-67. doi: 10.1113/EP085308. Epub 2015 Aug 4. Review.

12.

Clinical trials using antisense oligonucleotides in duchenne muscular dystrophy.

Koo T, Wood MJ.

Hum Gene Ther. 2013 May;24(5):479-88. doi: 10.1089/hum.2012.234. Epub 2013 May 2. Review.

PMID:
23521559
13.

Personalised genetic intervention for Duchenne muscular dystrophy: antisense oligomers and exon skipping.

Mitrpant C, Fletcher S, Wilton SD.

Curr Mol Pharmacol. 2009 Jan;2(1):110-21. Review.

PMID:
20021451
14.

Gene therapy for muscular dystrophy: lessons learned and path forward.

Mendell JR, Rodino-Klapac L, Sahenk Z, Malik V, Kaspar BK, Walker CM, Clark KR.

Neurosci Lett. 2012 Oct 11;527(2):90-9. doi: 10.1016/j.neulet.2012.04.078. Epub 2012 May 17. Review.

15.

Update on the treatment of Duchenne muscular dystrophy.

Rodino-Klapac LR, Mendell JR, Sahenk Z.

Curr Neurol Neurosci Rep. 2013 Mar;13(3):332. doi: 10.1007/s11910-012-0332-1. Review.

PMID:
23328943
16.

Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations.

Aartsma-Rus A, Fokkema I, Verschuuren J, Ginjaar I, van Deutekom J, van Ommen GJ, den Dunnen JT.

Hum Mutat. 2009 Mar;30(3):293-9. doi: 10.1002/humu.20918. Review.

PMID:
19156838
17.

Gene therapy for muscle disease.

Miyagoe-Suzuki Y, Takeda S.

Exp Cell Res. 2010 Nov 1;316(18):3087-92. doi: 10.1016/j.yexcr.2010.05.022. Epub 2010 May 24. Review.

PMID:
20580709
18.

Current status of pharmaceutical and genetic therapeutic approaches to treat DMD.

Pichavant C, Aartsma-Rus A, Clemens PR, Davies KE, Dickson G, Takeda S, Wilton SD, Wolff JA, Wooddell CI, Xiao X, Tremblay JP.

Mol Ther. 2011 May;19(5):830-40. doi: 10.1038/mt.2011.59. Epub 2011 Apr 5. Review.

19.

Exon skipping and Duchenne muscular dystrophy: hope, hype and how feasible?

Wilton SD, Fletcher S.

Neurol India. 2008 Jul-Sep;56(3):254-62. Review.

20.

The potential of exon skipping for treatment for Duchenne muscular dystrophy.

Partridge T.

J Child Neurol. 2010 Sep;25(9):1165-70. doi: 10.1177/0883073810371130. Epub 2010 Jun 2. Review.

Supplemental Content

Support Center